<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00718484</url>
  </required_header>
  <id_info>
    <org_study_id>IPM2002</org_study_id>
    <nct_id>NCT00718484</nct_id>
  </id_info>
  <brief_title>A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma</brief_title>
  <acronym>PICASSO</acronym>
  <official_title>A Phase II Multicenter, Parallel Group, Randomized Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Subjects With Unresectable or Metastatic Soft-tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziopharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziopharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled trial to evaluate the clinical benefit of palifosfamide tris&#xD;
      administered with doxorubicin in combination, compared with single-agent doxorubicin&#xD;
      administered in subjects diagnosed with unresectable or metastatic soft-tissue sarcoma (STS).&#xD;
      Subjects who meet the entry criteria will be randomized into 1 of 2 arms: either to receive&#xD;
      palifosfamide tris plus doxorubicin or treatment with single-agent doxorubicin. Subjects will&#xD;
      be anthracyclin naïve.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy analysis will be conducted on the intent-to-treat (ITT) population. All attempts will be made to conduct assessment of disease status every 6 weeks until progression of disease or initiating off protocol anti cancer therapies.</measure>
    <time_frame>Every 6 weeks until progression</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifosfamide Tris and Doxorubicin</intervention_name>
    <description>On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years&#xD;
&#xD;
          2. Histological or cytological documentation of sarcoma (excluding alveolar soft-part&#xD;
             sarcoma, chondrosarcoma, dermatofibrosarcoma, Ewing sarcoma, GIST, Kaposi sarcoma,&#xD;
             mixed mesodermal tumor, osteosarcoma, radiation induced sarcomas, and unresectable low&#xD;
             grade liposarcoma) who have failed ≤2 prior regimens including adjuvant therapy, or ≤1&#xD;
             prior regimen for metastatic/unresectable disease, and for whom treatment with&#xD;
             doxorubicin is considered medically acceptable. Prior treatment with IFOS is&#xD;
             acceptable.&#xD;
&#xD;
          3. Have measurable disease as per RECIST criteria (Appendix 2)&#xD;
&#xD;
          4. ECOG Performance Status of 0 or 1 (Appendix 3)&#xD;
&#xD;
          5. Anthracyclin naïve&#xD;
&#xD;
          6. Life expectancy of ≥12 weeks&#xD;
&#xD;
          7. Adequate bone marrow, liver, and renal function, as assessed by the following&#xD;
             laboratory requirements conducted within 14 days prior to dosing:&#xD;
&#xD;
               1. Hemoglobin ≥9.0 g/dL&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥1,500/mm3&#xD;
&#xD;
               3. Platelet count 100,000/mm3&#xD;
&#xD;
               4. Total bilirubin ≤1.5×ULN (upper limit of normal)&#xD;
&#xD;
               5. ALT and AST ≤2.5×ULN or 5×ULN with hepatic disease&#xD;
&#xD;
               6. Partial thromboplastin [PT]-INR/activated partial thromboplastin time [PTT]&#xD;
                  &lt;1.5×ULN (≤2.0×ULN for subjects on anticoagulation prophylactic regimen).&#xD;
                  Subjects who are being therapeutically anticoagulated with an agent such as&#xD;
                  Coumadin (warfarin sodium) or heparin are allowed provided there is no prior&#xD;
                  evidence of underlying abnormality in coagulation parameters. If an interaction&#xD;
                  between study drug and anticoagulant is suspected, anticoagulation monitoring&#xD;
                  should be increased as appropriate.&#xD;
&#xD;
               7. Serum creatinine ≤ULN&#xD;
&#xD;
          8. Written informed consent must be obtained from a potential subject prior to the&#xD;
             conduct of any study-specific procedures&#xD;
&#xD;
          9. Male and female subjects must agree to use adequate birth control measures/barrier&#xD;
             control during the course of the trial&#xD;
&#xD;
         10. Women of childbearing potential must have a urine pregnancy test performed within 14&#xD;
             days of the start of treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has any one of the following sarcoma sub types: alveolar soft-part sarcoma,&#xD;
             chondrosarcoma, dermatofibrosarcoma, Ewing sarcoma, GIST, Kaposi sarcoma, mixed&#xD;
             mesodermal tumor, osteosarcoma, radiation induced sarcomas, and unresectable low grade&#xD;
             liposarcoma.&#xD;
&#xD;
          2. Clinically evident congestive heart failure &gt;Class II of the New York Heart&#xD;
             Association (NYHA) guidelines (Appendix 4)&#xD;
&#xD;
          3. Serious, clinically significant cardiac arrhythmias, defined as the existence of an&#xD;
             absolute arrhythmia, or ventricular arrhythmias classified as Lown III, IV, or V&#xD;
             (Appendix 4)&#xD;
&#xD;
          4. History and/or signs of active coronary artery disease/ischemia with or without angina&#xD;
             pectoris&#xD;
&#xD;
          5. Serious myocardial dysfunction defined as scintigraphically (MUGA [multiple gated&#xD;
             acquisition scan], myocardial scintigram) or ultrasound-determined absolute left&#xD;
             ventricular ejection fraction (LVEF) &lt;45%&#xD;
&#xD;
          6. History of HIV infection&#xD;
&#xD;
          7. Prior nephrectomy or history of urinary tract obstruction&#xD;
&#xD;
          8. Active, clinically serious infection requiring systemic antibacterial, antifungal, or&#xD;
             antiviral therapy&#xD;
&#xD;
          9. Any major surgery within 3 weeks prior to start of treatment&#xD;
&#xD;
         10. Metastatic brain or meningeal tumors, unless the subject is &gt;6 months from definitive&#xD;
             therapy and has a negative imaging study within 4 weeks of study entry. In addition,&#xD;
             the subject must not be undergoing acute steroid therapy or taper (chronic steroid&#xD;
             therapy is acceptable, provided the dose is stable for 1 month prior to study start,&#xD;
             and following screening radiographic studies).&#xD;
&#xD;
         11. Previous malignancy (except cervical carcinoma in situ, adequately treated basal cell&#xD;
             carcinoma, or superficial bladder tumors [Ta, Tis, &amp; T1] or other malignancies&#xD;
             curatively treated &gt;5 years prior to entry)&#xD;
&#xD;
         12. Pregnancy or lactation&#xD;
&#xD;
         13. Substance abuse or medical, psychological, or social conditions that may interfere&#xD;
             with the subject's participation in the study or evaluation of the study results&#xD;
&#xD;
         14. Any condition that is unstable or could jeopardize the safety of a subject and his/her&#xD;
             compliance with the protocol requirements&#xD;
&#xD;
             In addition, use of the following therapies and medications-prior or concomitant-would&#xD;
             exclude a subject from this study:&#xD;
&#xD;
         15. Anticancer chemotherapy, immunotherapy, or any investigational drug therapy during the&#xD;
             study or within 4 weeks of study entry (6 weeks for Mitomycin C)&#xD;
&#xD;
         16. Prior treatment with doxorubicin&#xD;
&#xD;
         17. Radiotherapy within 4 weeks of study entry (palliative radiation to bone lesions is&#xD;
             permitted if started or planned prior to Cycle 1, Day 1)&#xD;
&#xD;
         18. Bone marrow transplant or stem cell rescue within 4 months of study entry&#xD;
&#xD;
         19. Growth factors such as G-CSF (granulocyte colony-stimulating factor/filgrastim), or&#xD;
             biological response modifiers within 3 weeks of study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan J Lewis, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ZIOPHARM Oncology, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa city</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lenaxa</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>July 16, 2008</study_first_submitted>
  <study_first_submitted_qc>July 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2008</study_first_posted>
  <last_update_submitted>January 29, 2014</last_update_submitted>
  <last_update_submitted_qc>January 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoma</keyword>
  <keyword>Soft Tissue Sarcoma</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>anthracyclin</keyword>
  <keyword>Palifosfamide</keyword>
  <keyword>IFOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

